Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...

(MENAFN- EIN Presswire) DelveInsight's Cold Agglutinin disease market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS , NV, UNITED STATES ...

LAS VEGAS , NV, UNITED STATES, January 27, 2025 /EINPresswire / -- DelveInsight's“Cold Agglutinin disease Market Insight, Epidemiology And Market Forecast - 2034′′ report offers an in-depth ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.